RAS: Striking at the Core of the Oncogenic Circuitry
Cancer is a devastating disease process that touches the lives of millions worldwide. Despite advances in our understanding of the genomic architecture of cancers and the mechanisms that underlie cancer development, a great therapeutic challenge remains. Here, we revisit the birthplace of cancer bio...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00965/full |
| _version_ | 1811286023885291520 |
|---|---|
| author | Ryan C. Gimple Ryan C. Gimple Xiuxing Wang |
| author_facet | Ryan C. Gimple Ryan C. Gimple Xiuxing Wang |
| author_sort | Ryan C. Gimple |
| collection | DOAJ |
| description | Cancer is a devastating disease process that touches the lives of millions worldwide. Despite advances in our understanding of the genomic architecture of cancers and the mechanisms that underlie cancer development, a great therapeutic challenge remains. Here, we revisit the birthplace of cancer biology and review how one of the first discovered oncogenes, RAS, drives cancers in new and unexpected ways. As our understanding of oncogenic signaling has evolved, it is clear that RAS signaling is not homogenous, but activates distinct downstream effectors in different cancer types and grades. RAS signaling is tightly controlled through a series of post-transcriptional mechanisms, which are frequently distorted in the context of cancer, and establish key metabolic and immunologic states that support cancer growth, migration, survival, metastasis, and plasticity. While targeting RAS has been fiercely pursued for decades, new strategies have recently emerged with the potential for therapeutic efficacy. Thus, understanding the complexities of RAS biology may translate into improved therapies for patients with RAS-driven cancers. |
| first_indexed | 2024-04-13T02:53:28Z |
| format | Article |
| id | doaj.art-b73fae02348b4be4a5bbf65b6a314fe9 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T02:53:28Z |
| publishDate | 2019-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b73fae02348b4be4a5bbf65b6a314fe92022-12-22T03:05:47ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-09-01910.3389/fonc.2019.00965492087RAS: Striking at the Core of the Oncogenic CircuitryRyan C. Gimple0Ryan C. Gimple1Xiuxing Wang2Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, San Diego, CA, United StatesDepartment of Pathology, Case Western University, Cleveland, OH, United StatesKey Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical University, Nanjing, ChinaCancer is a devastating disease process that touches the lives of millions worldwide. Despite advances in our understanding of the genomic architecture of cancers and the mechanisms that underlie cancer development, a great therapeutic challenge remains. Here, we revisit the birthplace of cancer biology and review how one of the first discovered oncogenes, RAS, drives cancers in new and unexpected ways. As our understanding of oncogenic signaling has evolved, it is clear that RAS signaling is not homogenous, but activates distinct downstream effectors in different cancer types and grades. RAS signaling is tightly controlled through a series of post-transcriptional mechanisms, which are frequently distorted in the context of cancer, and establish key metabolic and immunologic states that support cancer growth, migration, survival, metastasis, and plasticity. While targeting RAS has been fiercely pursued for decades, new strategies have recently emerged with the potential for therapeutic efficacy. Thus, understanding the complexities of RAS biology may translate into improved therapies for patients with RAS-driven cancers.https://www.frontiersin.org/article/10.3389/fonc.2019.00965/fullRAScancermetabolismimmunologymitogen activated kinasecancer therapy |
| spellingShingle | Ryan C. Gimple Ryan C. Gimple Xiuxing Wang RAS: Striking at the Core of the Oncogenic Circuitry Frontiers in Oncology RAS cancer metabolism immunology mitogen activated kinase cancer therapy |
| title | RAS: Striking at the Core of the Oncogenic Circuitry |
| title_full | RAS: Striking at the Core of the Oncogenic Circuitry |
| title_fullStr | RAS: Striking at the Core of the Oncogenic Circuitry |
| title_full_unstemmed | RAS: Striking at the Core of the Oncogenic Circuitry |
| title_short | RAS: Striking at the Core of the Oncogenic Circuitry |
| title_sort | ras striking at the core of the oncogenic circuitry |
| topic | RAS cancer metabolism immunology mitogen activated kinase cancer therapy |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.00965/full |
| work_keys_str_mv | AT ryancgimple rasstrikingatthecoreoftheoncogeniccircuitry AT ryancgimple rasstrikingatthecoreoftheoncogeniccircuitry AT xiuxingwang rasstrikingatthecoreoftheoncogeniccircuitry |